12 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Article Searches
Biogen Inc. (BIIB) Rises Higher Than Market: Key Facts https://www.zacks.com/stock/news/2214591/biogen-inc-biib-rises-higher-than-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2214591 Jan 23, 2024 - Biogen Inc. (BIIB) closed the most recent trading day at $251.68, moving +1.36% from the previous trading session.
Will Biogen Inc. (BIIB) Beat Estimates Again in Its Next Earnings Report? https://www.zacks.com/stock/news/2217370/will-biogen-inc-biib-beat-estimates-again-in-its-next-earnings-report?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-2217370 Jan 29, 2024 - Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Can Biogen (BIIB) Keep the Beat Streak Alive in Q4 Earnings? https://www.zacks.com/stock/news/2223511/can-biogen-biib-keep-the-beat-streak-alive-in-q4-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2223511 Feb 08, 2024 - Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have risen.
Where Are Biotech ETFs Headed After Q4 Earnings? https://www.zacks.com/stock/news/2226390/where-are-biotech-etfs-headed-after-q4-earnings?cid=CS-ZC-FT-etf_news_and_commentary-2226390 Feb 14, 2024 - Look into how Biotech ETFs performed after Q4 earnings.
Ionis' (IONS) Olezarsen Gets FDA's Orphan Tag for Rare Disease https://www.zacks.com/stock/news/2227293/ionis-ions-olezarsen-gets-fda-s-orphan-tag-for-rare-disease?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2227293 Feb 16, 2024 - FDA grants orphan drug status to Ionis' (IONS) olezarsen for treating familial chylomicronemia syndrome (FCS). An NDA for olezarsen is expected to be filed this year.
Biogen Inc. (BIIB) Stock Falls Amid Market Uptick: What Investors Need to Know https://www.zacks.com/stock/news/2239569/biogen-inc-biib-stock-falls-amid-market-uptick-what-investors-need-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2239569 Mar 12, 2024 - Biogen Inc. (BIIB) concluded the recent trading session at $227.36, signifying a -1.18% move from its prior day's close.
Biogen Inc. (BIIB) Stifel 2024 Virtual CNS Days (Transcript) https://seekingalpha.com/article/4679198-biogen-inc-biib-stifel-2024-virtual-cns-days-transcript?source=feed_sector_transcripts Mar 19, 2024 - Biogen Inc. (NASDAQ:NASDAQ:BIIB) Stifel 2024 Virtual CNS Days Conference March 19, 2024 10:00 AM ETCompany ParticipantsPriya Singhal - Head of Development...
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Can the Stock Move Higher? https://www.zacks.com/stock/news/2221865/biogen-inc-biib-expected-to-beat-earnings-estimates-can-the-stock-move-higher?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2221865 Feb 06, 2024 - Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis' (IONS) Eplontersen Gets Fast Track Tag for New Indication https://www.zacks.com/stock/news/2224200/ionis-ions-eplontersen-gets-fast-track-tag-for-new-indication?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2224200 Feb 09, 2024 - The FDA bestows a Fast Track designation to Ionis (IONS) and partner AstraZeneca's (AZN) eplontersen for treating adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
Here's What Key Metrics Tell Us About Biogen Inc. (BIIB) Q4 Earnings https://www.zacks.com/stock/news/2225441/here-s-what-key-metrics-tell-us-about-biogen-inc-biib-q4-earnings?cid=CS-ZC-FT-fundamental_analysis|nfm-2225441 Feb 13, 2024 - The headline numbers for Biogen Inc. (BIIB) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Pages: 12

Page 1